ICICI Direct has given Buy recommendation for Sun Pharmaceutical Industries with a target price of Rs. 965 in its research report issued on Nov 03, 2021

ICICI Direct’s research report on Sun Pharmaceutical Industries

Sun Pharma is world’s fourth largest specialty generic company with sales of US$3.8 billion & boasts of 43 manufacturing sites addressing segments like specialty products, branded generics, complex generics, pure generics and APIs. With a market share of 8.2%, Sun is ranked No. 1 in domestic formulations. It enjoys leadership position in 11 specialties based on prescription Revenue breakup: US formulation~ 30%, Indian branded~30%, Emerging markets~17%, RoW~14%, API & Others~6%

Outlook

We change our rating from HOLD to BUY due to more consistency on the specialty front and linear growth trajectory India formulations. We value Sun at Rs 965 i.e. 30x P/E on FY23E EPS

 

Leave a Reply

Your email address will not be published. Required fields are marked *